Oncology Clinical Trials Market Size Grows at a CAGR of 8.41%

Introduction

Straits Research released its highly anticipated report, “Global Oncology Clinical Trials Market Size & Outlook, 2026-2034.” According to the study, the market size is valued at USD 18.55 billion in 2025 and is anticipated to grow to USD 38.23 billion by 2034, registering a compound annual growth rate (CAGR) of 8.41%.

Market Dynamics

The market growth is primarily attributed to the increasing prevalence of cancer worldwide is driving the demand for more oncology clinical trials to develop effective therapies. For example, in February 2024, as per the WHO, global cancer cases are projected to rise to over 35 million annually by 2050, emphasizing the urgent need for new treatments and clinical research. This rising incidence of cancer fuels the demand for innovative clinical trials, supporting the growth of the oncology clinical trials market. Moreover, the establishment of new oncology research centers and improvements in clinical trial infrastructure in emerging markets is creating new opportunities in the field. For example, in April 2025, as per the National Library of Medicine, in 2024, China’s National Medical Products Administration (NMPA) launched initiatives to simplify trial approvals and increase the number of qualified trial sites, encouraging more international oncology studies in the region. Such expansion provides cost-effective trial options and access to larger patient pools, boosting global oncology clinical trial activities.

Market Highlights

• Phase: The Phase I segment dominated the market in 2025 with a revenue share of 35.26%.
• Type: The Prostate Cancer segment is expected to witness the highest CAGR (9.12%), owing to the increasing prevalence of prostate cancer among aging male populations and the rising focus on developing targeted therapies. 
• Study: The Interventional Studies segment dominated the market in 2025, with a revenue share of 75.63%.
• Regional Insights: North America dominates the market in 2025, with a 47.92% share, fuelled by advanced clinical research infrastructure and a growing patient pool.

Competitive Players

1. Hoffmann-La Roche Ltd
2. AstraZeneca
3. Merck & Co., Inc.
4. Gilead Sciences, Inc 
5. PARAXEL International Corporation
6. ICON plc
7. Syneos Health
8. Medpace
9. Novotech
10. Charles River Laboratories
11. Laboratory Corporation of America Holdings
12. Pfizer Inc.
13. Lilly USA, LLC
14. Novartis AG
15. Bristol-Myers Squibb Company
16. AbbVie Inc. 
17. Amgen Inc.
18. Sanofi
19. GSK plc.
20. Bayer AG
21. Others

Recent Developments

Segmentation

1. By Phase (2026-2034)
   1. Phase I
   2. Phase II
   3. Phase III
   4. Phase IV
2. By Type (2026-2034)
   1. Breast Cancer
   2. Melanoma Cancer
   3. Colorectal Cancer
   4. Prostate Cancer
   5. Lung Cancer
   6. Others
3. By Study (2026-2034)
   1. Interventional studies
   2. Observational studies
   3. Expanded access studies